Please use this identifier to cite or link to this item:
Title: Diffuse large B-cell lymphoma: A consensus practice statement from the Australasian Lymphoma Alliance.
Austin Authors: Wight, Joel C ;Hamad, N;Campbell, B A;Ku, M;Lee, K;Rose, H;Armytage, T;Latimer, M;Lee, H P;Lee, Sze Ting ;Dickinson, M;Khor, Richard ;Verner, E
Affiliation: Department of Haematology, Concord Repatriation General Hospital, Sydney, New South Wales, Australia
Austin Health
James Cook University, Townsville, Australia
School of Medicine, University of Sydney, Sydney, New South Wales, Australia
Anatomical Pathology Department, NSW Health Pathology, Concord Repatriation General Hospital, Sydney, New South Wales, Australia
Canberra Hospital, Canberra, Australia
Australian National University, Canberra, Australia
Flinders Medical Centre, Adelaide, Australia
St Vincent's Hospital, Melbourne, Victoria
Department of Haematology, Peter MacCallum Cancer Centre, Parkville, Victoria
School of Medicine, Deakin University Geelong, Victoria
Department of Clinical Pathology, University of Melbourne, Parkville, Victoria
Department of haematology, Gosford Hospital, Gosford, New South, UK
St Vincent's Clinical School, Sydney, University of New South UK
Department of Haematology, St Vincent's Hospital Sydney, Australia
School of Medicine, Sydney, University of Notre Dame Australia
Department of Radiation oncology, Peter MacCallum Cancer Centre, Parkville, Victoria
University Hospital Geelong, Victoria
The University of Melbourne, Melbourne, Australia
Townsville University Hospital, Townsville, Australia
Issue Date: 16-Sep-2021
Date: 2021-09-16
Publication information: Internal Medicine Journal 2021; online first: 16 September
Abstract: Diffuse large B-cell lymphoma (DLBCL) is the most common lymphoma subtype, accounting for 30-40% of lymphoma diagnoses. Though aggressive, cure is achievable in approximately 60% of cases with primary chemo-immunotherapy, and in a further substantial minority by salvage therapy and autologous stem cell transplantation. Despite promising activity in early phase clinical trials, no intensified or novel treatment regimen has improved outcomes over R-CHOP21 in randomised studies. However, there remain several areas of controversy including the most appropriate prognostic markers, CNS prophylaxis and the optimal treatment for patients with high-risk disease. This position statement presents an evidence-based synthesis of the literature for application in Australasian practice. This article is protected by copyright. All rights reserved.
DOI: 10.1111/imj.15533
ORCID: 0000-0002-3216-2392
Journal: Internal Medicine Journal
PubMed URL: 34532916
Type: Journal Article
Subjects: DLBCL
Appears in Collections:Journal articles

Show full item record

Page view(s)

checked on Apr 21, 2024

Google ScholarTM


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.